New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
05:29 EDTPLXProtalix announces first patient treated in Phase I/II study of Fabry patients
Protalix BioTherapeutics announced that the first patient has been treated in the company's phase I/II clinical trial of Fabry patients with PRX-102. PRX-102 is the company's proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy for the treatment of Fabry disease.
News For PLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
10:27 EDTPLXProtalix offers to produce ZMapp Ebola treatment, i24News reports
Israeli company Protalix offered its resources to help produce ZMapp, the experimental Ebola treatment from privately-held MAPP Pharmaceuticals that has been in short supply, i24News reported previously on September 7. The circulation of a report from unitedwithisrael.org, which points back to the prior i24 report on Protalix, may be contributing to the early session strength in in the stock, which is up 18% this morning, according to contacts. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use